-
This court case has been in the news of late and now with the current ruling, it adds on one more layer of responsibility to the Name Brand drug company, in other words when the generic versions come out and are prescribed, they can piggyback the exact same warnings, thus the name brand company is now...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-18-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, Pharma, Heatlhcare, Side Effects, Warnings, Lawsuits, liability, Generice drugs, drugs. name band drugs
-
I will once more mention a potential change of paradigms here with educating the public. Each patient who took the drug is unique. Do we have any information on other drugs they were taking at the same time? Groups will continue to advise against the use until the full facts are known...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-31-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, drugs, healthcare, Pharma, PHR, FDA, Marketing, paradigms, personal heatlh records
-
The bar has also risen on Venture Capital money and is harder to get, and so much of the research is still in the “Science” stage, there have been a few companies that have had failed products and just folded up and went away. This certainly leaves the door open for Pharma, who has the financials...
-
I wonder if all the name brand companies will one day have nothing but generics? (grin). There’s always this interesting topic too, biosimilars. “Because biosimilars aren't exact duplicates of the original drugs, they don't violate the original drug's patent , enabling legal distribution...
-
Whistle blowers today seem to be playing a role in the move towards transparency in more ways than one, not to mention the bounty that could be there if a case goes to court and wrongdoing is found to be the case. BD A New Jersey arbitrator ruled that a former Amgen sales rep can proceed with a...
-
However, their prescription drug unit faced the same problems as the rest of the Pharma industry. A smart investment in consumer products is helping hold things together for J and J. The consumer product division was purchased from Pfizer in 2006, which was the company purchased by Pfizer...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-14-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, personalized medicine, Genomics, Pharma, Pfizer, Phamaceuticals, Consumer Goods, J and J, Warner Lambert
-
As the article states, you don’t need marketing for cancer drugs, as the need is unfortunately already there, thus marketing for cancer drugs does not necessarily carry the same sales expense as do other drugs. We have all seen the “tiered plans” on what level drugs are listed with insurance coverage...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-13-2008
Filed under:
Filed under: Medically Related, Insurance, Other Items of Interest, My Commentaries, personalized medicine, Genomics, health insurance, Pharma, Prescriptions, Cancer, R and D, Science 2.0
-
This is somewhat of a strange story about an outdoor advertiser trying to offer Pfizer some free advertising with Viagra, but obviously the judge and Pfizer were not in agreement. The big missile was paraded around Manhattan with the Viva Viagra advertising on it, parked in front of Pfizer's headquarters...
-
That might explain a couple odd stories of earlier this year, like the pilot program of the “Fake commercials” being tested, but there has also been an attempt to increase awareness at YouTube with FDA material as well, perhaps to even encouraging a bit of humor as I found on this video on YouTube, which...
-
As this begins the week of the “Never-Never” rules with Medicare and with Sepsis being included on the hospital acquired listings, the group is calling for standards to prevent, which includes the use of minocycline and rifampin impregnated catheters. Severe sepsis is common, with over 750...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-03-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, healthcare, microsoft, Medical Records, Silverlight, Pharma, Cook Medical, CMS, Heatlhcare, Catheters, hospital acquired infections, Server 2008, Never-Never, Sepsis, Thomas Jefferson University, Line Sepsis, Vanderbilt University
-
Whistle blower case where Pharma Sales representative created an investigation and settlement. Whistle blowers can and do receive portions of settlements, and in this case there was $46 million. The uses marketed by Cephalon were not approved by the FDA. Doctors can prescribe...
-
In other words, this is called Business Intelligence. Lots of it out there to choose from and one from Microsoft specifically related to hospital management and budgets. Before the demise of Wall Street it wasn’t too long ago that I posted about the All Nighter they pulled to mine and try...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-26-2008
Filed under:
Filed under: Medically Related, Technology, Other Items of Interest, My Commentaries, Pharma, Biotech, Cancer, Business Intelligence, R and D, Wall Street, Pricing
-
The drug evaluation department has the largest increase, and oncologists were difficult to find as most make more money on the outside. I wonder if they can find enough for the drug side of the business, as it is changing every day with new applications and with more information to review, it's...
-
Interesting article with some good background information about drugs that are close to or are related to the "street drugs" as we know them. There are definitely a number of researchers who want to delve into this further, but with bad raps and being illegal in their "street drug"...
-
I am guessing this stands to be topic for all in the Pharma business to keep an eye on. There are those in the Indian government too with reservations. The whole idea here is to save money over what the same might cost in the US, as reported earlier, 1/5 is the cost for R and D, thus this...